In its upcoming report, Viatris (VTRS) is predicted by Wall Street analysts to post quarterly earnings of $0.62 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $3.68 billion, representing a year-over-year increase of 2.6%.
The current level reflects a downward revision of 1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Viatris metrics that are routinely monitored and predicted by Wall Street analysts.
The average prediction of analysts places 'Net Sales- Developed Markets' at $2.18 billion. The estimate points to a change of +2.8% from the year-ago quarter.
It is projected by analysts that the 'Net Sales- Greater China' will reach $631.67 million. The estimate indicates a change of +7.3% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Sales- JANZ' should arrive at $285.14 million. The estimate indicates a change of -6.7% from the prior-year quarter.
Analysts expect 'Net Sales- Emerging Markets' to come in at $558.47 million. The estimate indicates a change of +0.6% from the prior-year quarter.
Analysts predict that the 'Net Sales- Developed Markets- Brands' will reach $1.12 billion. The estimate indicates a change of 0% from the prior-year quarter.
Analysts forecast 'Revenues- Other revenues' to reach $11.55 million. The estimate indicates a change of -11.8% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- JANZ- Brands' will reach $145.53 million. The estimate points to a change of -9.3% from the year-ago quarter.
The combined assessment of analysts suggests that 'Net Sales- JANZ- Generics' will likely reach $139.62 million. The estimate indicates a year-over-year change of -3.9%.
The collective assessment of analysts points to an estimated 'Net Sales- Emerging Markets- Brands' of $443.10 million. The estimate indicates a year-over-year change of +6.5%.
Analysts' assessment points toward 'Net Sales- Emerging Markets- Generics' reaching $115.37 million. The estimate points to a change of -17% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Total Net Sales' should come in at $3.65 billion. The estimate points to a change of +2.4% from the year-ago quarter.
The consensus estimate for 'Net Sales- Developed Markets- Generics' stands at $1.06 billion. The estimate points to a change of +5.9% from the year-ago quarter.
View all Key Company Metrics for Viatris here>>>Shares of Viatris have experienced a change of +4.4% in the past month compared to the +3.5% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), VTRS is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Viatris Inc. (VTRS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).